Friedrich Asmus

Friedrich is Oxular’s Chief Medical Officer and has over 20 years of experience in leading clinical and translational research in industry and academia. He is a board-certified neurologist and pharmacist. For more than 10 years has successfully headed clinical development programs in the US, Europe, and Asia. Friedrich was a key strategic contributor for retinal anti‑VEGF and other ophthalmic therapies at Bayer Pharma including indications like diabetic macular edema, diabetic retinopathy, and retinal vein occlusions.

Friedrich worked on rare ophthalmic diseases at ProQR Therapeutics heading the intravitreal oligonucleotide program for genetic forms of Retinitis pigmentosa (RP) and as SVP of Clinical Development for an intravitreal cell therapy for RP at jCyte.

Friedrich holds a private lectureship for Neurology at the University Hospital of Tuebingen, Germany, where he was also Deputy Chair of the Department of General Neurology. Friedrich has published over 50 peer‑reviewed full articles in ophthalmology and neurology.